Related Experiment Video
Updated: May 7, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Conditioning the heart to prevent myocardial reperfusion injury during PPCI
1University College London Hospital, London, UK.
Insights
Primary percutaneous coronary intervention (PPCI) is key for ST-segment elevation myocardial infarction (STEMI) patients. Cardioprotective
Area of Science:
- Cardiology
- Cardiovascular Research
Background:
- Primary percutaneous coronary intervention (PPCI) is the standard reperfusion therapy for ST-segment elevation myocardial infarction (STEMI).
- Despite advances, STEMI patients undergoing PPCI face significant adverse cardiovascular events due to lethal myocardial reperfusion injury.
- Previous cardioprotective strategies have largely failed in clinical translation for PPCI.
Purpose of the Study:
- To review the therapeutic potential of cardiac 'conditioning' strategies as adjuncts to PPCI.
- To explore how conditioning protects the heart against lethal myocardial reperfusion injury in STEMI.
- To discuss the role of cardiac magnetic resonance (CMR) imaging in assessing these novel therapies.
Main Methods:
- Review of recent proof-of-concept clinical studies on cardiac conditioning.
- Analysis of mechanical conditioning strategies (e.g., ischaemic postconditioning, remote ischaemic preconditioning, therapeutic hypothermia, hyperoxaemia).
- Analysis of pharmacological conditioning strategies (e.g., cyclosporin-A, natriuretic peptide, exenatide).
- Evaluation of cardiac magnetic resonance (CMR) imaging for assessing therapeutic efficacy.
Main Results:
- Cardiac conditioning strategies show promise in reducing myocardial infarct size in STEMI patients.
- Mechanical and pharmacological conditioning can be used as adjuncts to PPCI.
- CMR imaging provides non-invasive assessment of key surrogate endpoints like infarct size and microvascular obstruction.
Conclusions:
- Cardiac conditioning represents a promising therapeutic approach to mitigate lethal myocardial reperfusion injury in STEMI patients undergoing PPCI.
- Further research and clinical validation are needed to optimize and implement these cardioprotective strategies.
- Advancements in CMR imaging facilitate the evaluation of novel adjunctive therapies to PPCI.
Abstract:
For patients presenting with a ST-segment elevation myocardial infarction (STEMI), early myocardial reperfusion by primary percutaneous coronary intervention (PPCI) remains the most effective treatment strategy for limiting myocardial infarct size, preserving left ventricular systolic function, and preventing the onset of heart failure. Recent advances in PCI technology to improve myocardial reperfusion and the introduction of novel anti-platelet and anti-thrombotic agents to maintain the patency of the infarct-related coronary artery continue to optimize PPCI procedure. However, despite these improvements, STEMI patients still experience significant major adverse cardiovascular events. One major contributing factor has been the inability to protect the heart against the lethal myocardial reperfusion injury, which accompanies PPCI. Past attempts to translate cardioprotective strategies, discovered in experimental studies to prevent lethal myocardial reperfusion injury, into the clinical setting of PPCI have been disappointing. However, a number of recent proof-of-concept clinical studies suggest that the heart can be 'conditioned' to protect itself against lethal myocardial reperfusion injury, as evidenced by a reduction in myocardial infarct size. This can be achieved using either mechanical (such as ischaemic postconditioning, remote ischaemic preconditioning, therapeutic hypothermia, or hyperoxaemia) or pharmacological (such as cyclosporin-A, natriuretic peptide, exenatide) 'conditioning' strategies as adjuncts to PPCI. Furthermore, recent developments in cardiac magnetic resonance (CMR) imaging can provide a non-invasive imaging strategy for assessing the efficacy of these novel adjunctive therapies to PPCI in terms of key surrogate clinical endpoints such as myocardial infarct size, myocardial salvage, left ventricular ejection fraction, and the presence of microvascular obstruction or intramyocardial haemorrhage. In this article, we review the therapeutic potential of 'conditioning' to protect the heart against lethal myocardial reperfusion injury in STEMI patients undergoing PPCI.
More Related Videos
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
10:01Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures
Published on: March 12, 2018